Morgan Stanley analyst Terence Flynn upgraded Vertex Pharmaceuticals (VRTX) to Overweight from Equal Weight with a price target of $516, up from $438. The firm is taking a more positive stance on the company’s kidney franchise pipeline, including Pove and Inaxaplin. If the drugs are successful in Phase 3, with key data coming in 2026, they will accelerate Vertex’s earnings and revenue growth and drive diversification away from cystic fibrosis, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals: Strategic Diversification and Promising Pipeline Justify Buy Rating
- Nike upgraded, Dollar Tree downgraded: Wall Street’s top analyst calls
- Scotiabank starts 10 large cap drugmakers with ‘out-of-consensus’ positive view
- Vertex Pharmaceuticals initiated with an Outperform at Scotiabank
- Buy These 3 Stocks Now, Say Five-Star Analysts – November 11, 2025